A nationwide study found a marked increase in new GLP-1RA prescriptions over the last decade, particularly since 2020. Semaglutide was the most prescribed GLP-1RA, by far, in 2023…. read more.
Irregular sleep duration appears to be associated with an increased risk of diabetes, researchers reported on July 17, 2024 in Diabetes Care. “Our study identified a modifiable lifestyle… read more.
Semaglutide significantly reduces risk of major kidney disease events, cardiovascular outcomes and mortality in patients with type 2 diabetes and chronic kidney disease, groundbreaking study reveals A pioneering… read more.
Thiazolidinediones (TZDs) are a class of drug that can be used to treat type 2 diabetes by reversing insulin resistance, one of the main hallmarks of the disease…. read more.
New research being presented at this year’s European Congress on Obesity (ECO) in Venice, Italy (12-15 May), suggests that replacing sugar-sweetened food and drinks with low/no energy sweetened… read more.
The body’s inability to produce enough insulin or use it effectively often results in type 2 diabetes (T2D), a chronic disease affecting hundreds of millions of people around… read more.
People with type 2 diabetes who underwent bariatric surgery achieved better long-term blood glucose control compared to people who received medical management plus lifestyle interventions, according to a… read more.
Subjects from a weight loss trial who achieved any remission from Type 2 diabetes also achieved a 40% lower rate of cardiovascular disease (CVD) and a 33% lower… read more.
Glucagon-like receptor agonists (GLP-1 RAs), a class of type 2 diabetes drug treatments, appear to also reduce the risk of colorectal cancer (CRC) researchers reported on Dec. 7,… read more.
Materials engineers at Stanford University have developed a novel hydrogel drug delivery system that transforms daily or weekly injections of diabetes and weight control drugs like Ozempic, Mounjaro,… read more.
Investigators have implemented an automated health maintenance tool created by the National Kidney Foundation into electronic medical records to prompt primary care physicians to screen for chronic kidney… read more.
Tirzepatide. a once weekly GIP and GLP-1 receptor agonist, treats early-onset type 2 diabetes as effectively as it treats type 2 diabetes diagnosed later in life, researchers reported… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
